Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis
Public ClinicalTrials.gov record NCT00388505. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study compares the safety of the tobramycin solution for inhalation with the tobramycin dry powder formulation, used with a simple inhaler
Study identification
- NCT ID
- NCT00388505
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 517 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2006
- Primary completion
- Feb 28, 2009
- Completion
- Feb 28, 2009
- Last update posted
- Jul 23, 2012
2006 – 2009
United States locations
- U.S. sites
- 24
- U.S. states
- 12
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Hartford | Connecticut | 06102 | — |
| Emory University CF Center | Atlanta | Georgia | 30322 | — |
| Rush University Center | Chicago | Illinois | 60612 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02115 | — |
| Novartis Investigative Site | Lebanon | New Hampshire | 03756 | — |
| Novartis Investigative Site | Livingston | New Jersey | 07039 | — |
| Novartis Investigative Site | Long Branch | New Jersey | 07740 | — |
| Novartis Investigative Site | Morristown | New Jersey | 07967 | — |
| Novartis Investigative Site | Somerset | New Jersey | 08873 | — |
| Novartis Investigative Site | Albany | New York | 12208 | — |
| Novartis Investigative Site | Buffalo | New York | 14222 | — |
| Novartis Investigative Site | New Hyde Park | New York | 11040 | — |
| Novartis Investigative Site | New York | New York | 10011 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Novartis Investigative Site | Stony Brook | New York | 11794 | — |
| Novartis Investigative Site | Syracuse | New York | 13210 | — |
| Novartis Investigative Site | Valhalla | New York | 10595 | — |
| Penn State College of Medicine | Hershey | Pennsylvania | 17033 | — |
| Drexel University College of Medicine | Philadelphia | Pennsylvania | 19102 | — |
| Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| Novartis Investigative Site | Burlington | Vermont | 05401 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22903 | — |
| West Virginia University Health Sciences Center | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
Recently updated Cystic Fibrosis trials
Other public records listing Cystic Fibrosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT05548283: Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study Recruiting
- NCT04509050: Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children Recruiting
- NCT06057714: Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis Recruiting
- NCT03655223: Early Check: Expanded Screening in Newborns Active, not recruiting
- NCT03161808: Rare CFTR Mutation Cell Collection Protocol (RARE) Recruiting
- NCT05422222: Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00388505, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2012 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00388505 live on ClinicalTrials.gov.